<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Comparison of ICP Guidelines: 2011 vs 2022</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.3.1/reveal.min.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.3.1/theme/white.min.css">
    <style>
        .reveal h1, .reveal h2, .reveal h3, .reveal h4, .reveal h5, .reveal h6 {
            text-transform: none;
        }
        .reveal ul {
            display: block;
        }
        .reveal ol {
            display: block;
        }
        .reveal section img {
            border: none;
            box-shadow: none;
        }
    </style>
</head>
<body>
    <div class="reveal">
        <div class="slides">
            <section>
                <h1>Comparison of ICP Guidelines:<br>2011 vs 2022</h1>
            </section>

            <section>
                <h2>1. Introduction</h2>
                <p>This presentation compares the old (2011) and new (2022) guidelines on Intrahepatic Cholestasis of Pregnancy (ICP), including relevant statistics and findings.</p>
            </section>

            <section data-auto-animate>
                <h2>2. Prevalence</h2>
                <h3>Old (2011):</h3>
                <ul>
                    <li>0.7% in multi-ethnic populations in England</li>
                    <li>1.2-1.5% in women of Indian-Asian or Pakistani-Asian origin</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>2. Prevalence</h2>
                <h3>New (2022):</h3>
                <ul>
                    <li>Maintains the same prevalence statistics</li>
                </ul>
                <h3>Similarity:</h3>
                <p>Both guidelines acknowledge variation in prevalence among different populations</p>
            </section>

            <section data-auto-animate>
                <h2>3. Diagnostic Criteria</h2>
                <h3>Old (2011):</h3>
                <ul>
                    <li>Pruritus in pregnancy</li>
                    <li>Abnormal liver function tests (LFTs) beyond pregnancy-specific limits</li>
                    <li>No specific bile acid threshold mentioned</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>3. Diagnostic Criteria</h2>
                <h3>New (2022):</h3>
                <ul>
                    <li>Pruritus in pregnancy</li>
                    <li>Raised peak random total bile acid concentration of ≥19 μmol/L</li>
                    <li>Normal pregnancy-specific upper limit for bile acids: 18 μmol/L</li>
                </ul>
                <h3>Key Difference:</h3>
                <p>New guideline emphasizes specific bile acid threshold for diagnosis</p>
            </section>

            <section data-auto-animate>
                <h2>4. Risk Stratification</h2>
                <h3>Old (2011):</h3>
                <p>Did not provide clear risk stratification based on bile acid levels</p>
            </section>

            <section data-auto-animate>
                <h2>4. Risk Stratification</h2>
                <h3>New (2022):</h3>
                <p>Categorizes ICP based on peak bile acid levels:</p>
                <ul>
                    <li>Mild: 19-39 μmol/L</li>
                    <li>Moderate: 40-99 μmol/L</li>
                    <li>Severe: ≥100 μmol/L</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>4. Risk Stratification</h2>
                <h3>Stillbirth Risk (New guideline):</h3>
                <ul>
                    <li>Mild ICP: 0.13% (similar to background risk)</li>
                    <li>Moderate ICP: 0.28%</li>
                    <li>Severe ICP: 3.44%</li>
                    <li>UK national stillbirth rate (2015): 0.29%</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>5. Fetal Monitoring</h2>
                <h3>Old (2011):</h3>
                <ul>
                    <li>Suggested various monitoring techniques (e.g., CTG, ultrasound)</li>
                    <li>Acknowledged limitations in predicting fetal death</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>5. Fetal Monitoring</h2>
                <h3>New (2022):</h3>
                <ul>
                    <li>States that ultrasound and CTG do not predict or prevent stillbirth</li>
                    <li>Emphasizes maternal monitoring of fetal movements</li>
                </ul>
                <h3>Key Change:</h3>
                <p>New guideline is more explicit about limitations of fetal monitoring in preventing adverse outcomes</p>
            </section>

            <section data-auto-animate>
                <h2>6. Associated Risks</h2>
                <h3>Preterm Birth (New guideline):</h3>
                <ul>
                    <li>Mild ICP: 16.5%</li>
                    <li>Moderate ICP: 19.1%</li>
                    <li>Severe ICP: 30.5%</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>6. Associated Risks</h2>
                <h3>Other Risks (New guideline):</h3>
                <ul>
                    <li>Pre-eclampsia: OR 3.7 (95% CI 3.2-4.3)</li>
                    <li>Gestational diabetes: OR 2.4 (95% CI 2.1-2.8)</li>
                    <li>Meconium-stained amniotic fluid: OR 2.60 (95% CI 1.62-4.16)</li>
                </ul>
                <p>Old guideline did not provide such detailed risk statistics</p>
            </section>

            <section data-auto-animate>
                <h2>7. Treatment - Ursodeoxycholic Acid (UDCA)</h2>
                <h3>Old (2011):</h3>
                <ul>
                    <li>Suggested UDCA might be beneficial</li>
                    <li>Limited evidence from small studies</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>7. Treatment - Ursodeoxycholic Acid (UDCA)</h2>
                <h3>New (2022):</h3>
                <ul>
                    <li>Does not routinely recommend UDCA for improving perinatal outcomes</li>
                    <li>Based on larger randomized controlled trials</li>
                    <li>May reduce maternal itch by about 5mm on a 100mm scale</li>
                    <li>May reduce spontaneous preterm birth &lt;37 weeks (aOR 0.46, 95% CI 0.25-0.86)</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>8. Timing of Delivery</h2>
                <h3>Old (2011):</h3>
                <ul>
                    <li>Suggested considering delivery around 37-38 weeks</li>
                    <li>No clear stratification based on severity</li>
                </ul>
            </section>

            <section data-auto-animate>
                <h2>8. Timing of Delivery</h2>
                <h3>New (2022):</h3>
                <ul>
                    <li>Mild ICP: Consider planned birth by 40 weeks</li>
                    <li>Moderate ICP: Consider planned birth at 38-39 weeks</li>
                    <li>Severe ICP: Consider planned birth at 35-36 weeks</li>
                </ul>
                <h3>Key Change:</h3>
                <p>New guideline provides more nuanced recommendations based on severity</p>
            </section>

            <section data-auto-animate>
                <h2>9. Long-term Maternal Health</h2>
                <h3>New (2022) guideline includes long-term health data:</h3>
                <ul>
                    <li>Increased risk of hepatobiliary disease: HR 2.62 (95% CI 2.47-2.77)</li>
                    <li>Increased risk of gallstone disease: HR 2.72 (95% CI 2.55-2.91)</li>
                    <li>Increased risk of immune-mediated diseases: HR 1.28 (95% CI 1.19-1.38)</li>
                </ul>
                <p>Old guideline did not include long-term follow-up data</p>
            </section>

            <section>
                <h2>10. Conclusion</h2>
                <p>The 2022 guideline reflects significant advancements in our understanding of ICP:</p>
                <ul>
                    <li>More precise diagnostic criteria with specific bile acid thresholds</li>
                    <li>Clearer risk stratification based on bile acid levels</li>
                    <li>More nuanced management strategies, especially regarding timing of delivery</li>
                    <li>Greater caution in interventions without clear evidence of benefit (e.g., UDCA, fetal monitoring)</li>
                    <li>Inclusion of long-term maternal health data</li>
                </ul>
                <p>These changes aim to improve care for women with ICP while providing more personalized management based on disease severity.</p>
            </section>
        </div>
    </div>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/reveal.js/4.3.1/reveal.min.js"></script>
    <script>
        Reveal.initialize({
           hash: true,
				  plugins: [ RevealMarkdown, RevealHighlight, RevealNotes ],
				  autoAnimate: true,
				  autoAnimateEasing: 'ease-out',
				  autoAnimateDuration: 0.8,
				  autoAnimateUnmatched: false,
				  center: true,
				  transition: 'slide',
			  	backgroundTransition: 'fade',
				
				// Fit text
			  	width: "100%",
			  	height: "100%",
			  	margin: 0,
			  	minScale: 0.2,
			  	maxScale: 2.0
            plugins: [ ]
        });
    </script>
</body>
</html>
